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Abstract 
Aim: The aim of this study was emphasizing the need for a more systematic monitoring of patients 
diagnosed with HCV in Croatia. 
Methods: From 2014 to 2018, at the University Hospital for Infectious Diseases, sera from 23,524 
patients were tested for HCV. Confirmatory testing was performed by Western Blot. Adult patients 
with an anti-HCV positive screening test were analysed. HCV RNA was quantified by real-time PCR, 
while HCV genotypes and subtypes were determined by PCR and the reverse hybridization method. 
Results: A total of 428 anti-HCV ELISA-positive adults were analysed (68.7% males, 31.3% females, 
median age 43 years, range 19-88 years). Hepatitis C was confirmed by WB in 390, while 28 patients 
had borderline WB results. Anti-HCV was not confirmed by WB in 10 patients. HCV RNA was tested 
in 331 patients and viremia was detected in 218 patients. There was no data on HCV RNA in 97 patients 
(22.66%). HCV genotypes/subtypes were determined in 185 of 218 anti-HCV WB positive patients. 
Genotype 1 was detected in 97/185 (52.43%), genotype 2 was detected in 3/185 (1.62%), while subtype 
3a was detected in 76/185 (41.08%) and genotype 4 in 9/185 patients (4.86%). 
Conclusion: In a five-year period, the HCV seroprevalence rate in subjects tested at the University 
Hospital for Infectious Diseases was 1.81%. According to the data analysed, almost one quarter of 
patients with detected anti-HCV antibodies were not treated further, which indicates the need for a 
systematic monitoring of patients diagnosed with HCV. It is necessary to determine viremia after a 
positive anti-HCV screening result in order to initiate treatment and prevent HCV-related 
complications.  
(Radmanić L, Cetinić Balent N, Šimičić P, Vince A, Židovec Lepej S, Đaković Rode O. The Need for 
Systematic Monitoring and Improved Surveillance of Hepatitis C Patients in Croatia. SEEMEDJ 2020; 
4(2); 28-34) 
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Introduction 
Both a general practitioner and a secondary-
care specialist are involved in the diagnosis of 
chronic viral hepatitis and in the clinical 
management of infected patients [1]. The initial 
diagnosis and management of chronic hepatitis 
relies on primary-care physicians to identify and 
screen patients who were in contact with 
hepatitis C, since most people with chronic 
hepatitis are asymptomatic until the 
development of cirrhosis or hepatocellular 
carcinoma [2]. The WHO recommends 
education of primary care physicians about the 
risks factors of acquiring HCV infection and 
encourages increased activity in finding new 
patients in screening programs.  
Approximately 71 million people worldwide 
have chronic hepatitis C, of which 15 million in 
Europe, and about 400,000 people in the world 
die from the effects of hepatitis C per year. 
Croatia is a country with a low incidence rate of 
hepatitis C. It is estimated that 40,000 people are 
anti-HCV positive in Croatia. In May 2016, the 
World Health Assembly endorsed the Global 
Health Sector Strategy on viral hepatitis, which 
proposed to eliminate viral hepatitis as a public 
health threat by 2030. Elimination of viral 
hepatitis as a public health threat requires 90% 
reduction in incidence and 65% reduction in 
mortality in comparison with the 2015 baseline, 
along with the improvement of viral hepatitis 
diagnostic coverage up to 90% and treatment of 
80% of eligible patients [4]. To reach these 
targets, the WHO Regional Office for Europe is 
encouraging Member States to plan and 
strengthen national responses to viral hepatitis 
through awareness-raising, surveillance, 
prevention, strengthening of laboratory capacity 
and provision of guidance on testing and 
treatment [5]. Implementation of the Global 
Health Sector Strategy would prevent 7.1 million 
deaths between 2015 and 2030 [4].  
Hepatitis C virus (HCV) diagnostics starts with 
determination of anti-HCV antibodies [3,6]. Each 
positive anti-HCV screening result requires 
further HCV RNA detection in order to confirm 
actual contact with HCV in the past. If HCV RNA 
is negative, positive anti-HCV results should be 
confirmed by Western immunoblotting (WB) 
[7,8]. In 2019, WHO recommended offering 
treatment with direct acting antivirals (DAA) to all 
individuals diagnosed with HCV infection who 
are 12 years of age or older, irrespective of 
disease stage (with the exception of pregnant 
women) [9]. Priority for treatment is defined by 
the stage of fibrosis, the risk of progression to 
advanced disease, the presence of extrahepatic 
manifestations and comorbidities, patients with 
HBV or HIV coinfection and patients with 
indication for organ transplantation [10].  
The aim of this study was emphasizing the need 
for a systematic monitoring of patients 
diagnosed with HCV. This must include the 
determination of viremia after a positive anti-
HCV screening result in order to administer a 
corresponding therapy since, according to the 
data analysed, almost one quarter of patients 
with detected anti-HCV antibodies are not 
treated further. 
Patients and Methods  
From 2014 to 2018, at the University Hospital for 
Infectious Diseases in Zagreb, sera from 23,524 
patients were tested for anti-HCV antibodies by 
using either enzyme immunoassay (ELISA) for 
simultaneous detection of anti-HCV antibodies 
and capsid antigen (HCV Ag-Ab) or only anti-
HCV antibody determination (BioRad, France). 
As required, each of the 428 positive ELISA sera 
was confirmed by Western Blot (INNO-LIA HCV 
Score Fujirebio; recomLine HCV IgG Mikrogen). 
HCV RNA was quantified by real-time PCR 
(Abbott RealTime HCV) and HCV genotypes and 
subtypes were determined by PCR and the 
reverse hybridization (INNO-LiPA HCV 
Genotyping) method. 
Results 
This study included 428 anti-HCV ELISA-positive 
adults who were newly diagnosed in the period 
from 2014 to 2018 and over 18 years of age. 
Median age of patients was 43 years, ranging 
from 19 to 88 years. Regarding gender, 68.7% of 
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the patients were male and 31.3% were female. 
According to the available diagnoses from the 
referral, 293 (293/428; 68.45%) patients had 
chronic hepatitis or elevated hepatic lesion, 52 
(52/428; 12.14%) patients were injecting drug 
users and 83 (83/428; 19.39%) patients had other 
diagnoses, for example, neurological and 
muscular diseases and factors affecting the 
health system.  
Anti-HCV was confirmed by Western Blot in 390 
patients (91.12%), while 28 patients (6.54%) had 
borderline Western Blot results. When it comes 
to borderline Western Blot results, negative 
result was confirmed with molecular testing in 
16 patients, HCV infection was excluded in two 
patients with paired sera and infection status 
was unknown in 10 patients. Positive anti-HCV 
ELISA was not confirmed by Western Blot in 10 
patients (2.34%). Molecular testing for HCV RNA 
was performed in 331 patients – 65.86% (218/331) 
of the patients had measurable viremia (Table 1).  
 
Table 1. Results of Western Blot and HCV RNA in anti-HCV (ELISA) positive patients tested at UHID 
anti-HCV 
HCV RNA Patients  N (%) Enzyme-linked 





Positive 218 (65.86) 
  Negative 87 (26.28) 
Positive Borderline Negative 16 (4.83) 
Positive Negative Negative 10 (3.02) 
TOTAL   331 (100.00) 
 
Median viremia was 456.024.5 IU/ml (range 78-
43.041.938 IU RNA HCV/mL). HCV RNA was not 
detected in 87 patients with positive HCV WB, 16 
with borderline and 10 with negative HCV WB. 
There was no data on HCV RNA testing at the 
UHID for 85 patients with positive and 12 with 
borderline HCV WB (97/428; 22.66%) (Table 2).  
Table 2. Results of Western Blot and HCV RNA in anti-HCV (ELISA) positive patients 
anti-HCV 
HCV RNA Patients  N (%) Enzyme-linked 
immunoassay Western Blot 
Positive Positive 
Positive 218 (50.93) 
Negative 87 (20.33) 
Unknown 85 (19.86) 
Positive Borderline 
Negative 16 (3.74) 
Unknown 12 (2.80) 
Positive Negative Negative 10 (2.34) 
TOTAL  428 (100.00) 
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According to the available diagnoses from the 
referral, 48 of 97 patients with positive anti-HCV 
ELISA and unknown viremia were patients who 
had chronic hepatitis or elevated hepatic lesion 
(49.48%). Seventeen of 97 patients were injecting 
drug users (17.52%) and 32 of 97 patients had 
other diagnoses, for example, neurological and 
muscular diseases and factors affecting the 
health system (32.99%).  
HCV genotypes and subtypes were determined 
in 185 of 218 anti-HCV WB positive patients with 
HCV RNA >1.000 IU/ml in the serum. Genotype 1 
was detected in 97 (97/185; 52.43%) patients, 
genotype 2 in 3 (3/185; 1.62%) patients, subtype 
3a in 76 (76/185; 41.08%) /185 and genotype 4 in 
9 (9/185; 4.86%) patients. Subtypes 1a and 1b of 
genotype 1 were further distinguished. Subtype 
1a was detected in 57 (57/97; 58.76%) patients 
and subtype 1b in 36 (36/97; 37.11%) patients. In 
four patients, the subtype of genotype 1 could 
not be determined (Figure 1). 
 
 
Figure 1. HCV genotype/subtype distribution in HCV RNA-positive patients (n = 185) 
 
Discussion 
HCV prevalence estimates range from 0.4% to 
5.2% in the world, with countries in the north and 
west of Europe having lower estimates (0.9%) 
than countries in the east of Europe (3.3%) [11,12]. 
In a five-year period, HCV seroprevalence rate in 
subjects diagnosed at the UHID was 1.81%, which 
was slightly higher than the estimate (0.8-1.0%) 
for the Croatian population [13]. However, most 
of the data on prevalence was obtained through 
the serological testing of samples from 
voluntary blood donors, who were a strictly 
controlled group. HCV prevalence in blood 
donors continuously declined from 1.38% in 1992 
to 0.0009% in the last decade. Therefore, it is to 
be expected that the actual prevalence in the 
general population is higher [13,14]. 
Nevertheless, this data suggests that HCV 
seroprevalence in Croatia is most similar to the 
seroprevalence rate in western European 
countries.  
According to the latest analysis on the 
distribution of HCV genotypes and subtypes in 
Croatia, Croatian patients were mostly infected 
with HCV genotype 1 (56.63%), followed by 
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genotype 3 (37.23%), genotype 4 (4.21%) and 
genotype 2 (1.83%). This is very similar to our 
data, according to which genotype 1 was 
detected in 52.43% patients, genotype 2 in 1.62% 
patients, subtype 3a in 41.08% and genotype 4 in 
4.86% patients [15]. However, genotype 1 
subtyping showed 58.76% of subtype 1a 
infections and 37.11% subtype 1b infections in our 
study, while national studies suggest a higher 
prevalence of subtype 1b in Croatia [15,16].  
Our cohort study tested 23,524 patients for anti-
HCV antibodies to show how many adults with a 
positive anti-HCV screening result were 
accurately diagnosed, including determination 
of viremia, in the period from 2014 to 2018. 
Epidemiological and clinical data from the 
referrals and the UHID database suggest that 
218 of 331 patients who were molecularly tested 
at the UHID had measurable viremia, while there 
was no data for 97 anti-HCV-positive patients. 
This suggests the possibility they were tested at 
another institution or that they were simply not 
treated further. This indicates the need for a 
more systematic monitoring and determination 
of viremia in potential patients in order to initiate 
treatment. According to the available diagnoses 
from the referral, 17.50% of the patients were 
people who injected drugs and, probably due to 
their lifestyle, were lost to secondary specialist 
care. Furthermore, 49.50% of the patients were 
people who had chronic hepatitis or elevated 
hepatic lesion and 33% of the patients were 
people with other diagnoses, for example, 
neurological and muscular diseases and factors 
affecting the health system. Since injecting drug 
use is one of the most efficient routes for HCV 
transmission, there is a very high prevalence of 
HCV in people who inject drugs in most 
European countries, while in Croatia it ranges 
from 29% to 65%, depending on the 
geographical region [13]. 
According to Becchini et al., general 
practitioners’ role and referral back to primary 
care vary within and between countries – most 
general practitioners are rarely involved in 
monitoring clinical outcomes other than some 
side effects among patients undergoing antiviral 
treatment [1,8]. A lack of uniform practice 
suggests that in some patients with serologically 
confirmed presence of the infection, additional 
nucleic acid testing may not always be 
performed. Therefore, the role of the general 
practitioner and specialists involved in clinical 
management of chronically infected patients 
should be clarified in order to ensure that the 
patients are followed-up and accurately 
diagnosed [1]. The Croatian Reference Centre for 
Diagnostics and Treatment of Viral Hepatitis 
performs initial check-ups of patients with acute 
and chronic hepatitis B and hepatitis C infection, 
serological and molecular testing to detect 
parameters of virus infection, pretreatment 
evaluation of the patients (liver biopsy, 
Fibroscan) along with treatment and monitoring 
of patients after the end of treatment. National 
Reference Centre also provides strategies and 
guidelines for optimization of diagnostics and 
standardization of treatment of viral hepatitises 
[17]. However, in Croatia, there is no National 
Hepatitis Treatment Registry used by all 
physicians prescribing DAAs and patients are 
diagnosed and treated at various institutions 
across the country. Such decentralization 
enables easier access to care for patients, 
whereas an early diagnosis and successful 
treatment not only prevent HCV-related 
complications, but also stop infectiousness. On 
the other hand, it is possible that the monitoring 
of patients and overview of the treatment 
process is better in specialized, centralized 
settings than in unspecialized, decentralized 
settings [18]. 
Conclusion 
It is necessary to improve the monitoring and 
surveillance of hepatitis C patients in Croatia 
since almost one quarter of patients with 
detected anti-HCV antibodies are not treated 
further. Determination of viremia after positive 
anti-HCV screening would ensure adequate 
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